No Data
No Data
Reported Sunday, Gilead's Kite Highlights New Data Showcasing Yescarta's Curative Potential In Relapsed/Refractory Large B-Cell Lymphoma At ASH 2024
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
Weekly Buzz: Now THOSE are records!!
Wells Fargo's 'Value Equity' List: VZ, GM, TGT and More
Index Records are BACK for Friday Market While Unemployment Climbs | Live Stock
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105